MedTrace Logo

A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples

NCT02189330 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-07-15

No results posted yet for this study

Summary

All subjects in this study will be given tafamidis. After swallowing a single pill of tafamidis, measurements including blood samples will be compared to see if tafamidis made in different ways is about the same. After approximately 28 days subjects will be given another pill of tafamidis and the study measurements will be repeated.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Tafamidis

20 mg of current commercial formulation.

DRUG

Tafamidis

12.2 mgA free acid tablet.

DRUG

Tafamidis

20 mg new soft gelatin capsule.

DRUG

Tafamidis

4 capsules of 20 mg tafamidis of current commercial formulation.

DRUG

Tafamidis

4 capsules of 12.2 mg tafamidis of free acid tablet..

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02189330 on ClinicalTrials.gov